Stockscreener 앱 받기
4.00
6.10%
0.23
시간 외 거래:
4.00
4 D Molecular Therapeutics Inc 주식(FDMT)의 최신 뉴스
Cystic Fibrosis Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Oligonucleotides Clinical Trial Pipeline Analysis Demonstrates 280+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - SINA HONG KONG LIMITED
Gene Therapy in Ophthalmology Market Set to Transform Vision Restoration Landscape by 2034 | Says DelveInsight - Barchart.com
Harbor Capital Advisors Inc. Invests $99,000 in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Position Raised by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (D-)” Rating at Weiss Ratings - Defense World
908 Devices’ (MASS) “Sell (D-)” Rating Reiterated at Weiss Ratings - Defense World
Organigram (TSE:OGI) Stock Price Up 2% – Should You Buy? - Defense World
Analysts Issue Forecasts for FDMT FY2026 Earnings - Defense World
Vivani Medical Appoints Anthony Baldor as Chief Financial Officer - The Manila Times
Cantor Fitzgerald Forecasts UTHR FY2026 Earnings - Defense World
Cantor Fitzgerald Forecasts UBER FY2026 Earnings - Defense World
Cantor Fitzgerald Forecasts TYL FY2026 Earnings - Defense World
Analysts Set Expectations for SHLS FY2026 Earnings - Defense World
Equities Analysts Offer Predictions for VYGR FY2026 Earnings - Defense World
Cantor Fitzgerald Predicts TG Therapeutics FY2026 Earnings - Defense World
Analysts Set Expectations for SLNO FY2026 Earnings - Defense World
Equities Analysts Offer Predictions for SPWR FY2026 Earnings - Defense World
Brokers Set Expectations for XENE FY2026 Earnings - Defense World
Fabry Disease Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight - GlobeNewswire
4D Molecular Therapeutics Being Investigated on Behalf of 4D Molecular Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates - MSN
ProShare Advisors LLC Increases Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Bank of America Corp DE Buys 127,885 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Two Sigma Investments LP Acquires 208,021 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Tesco (LON:TSCO) Stock Crosses Above 200-Day Moving Average – Should You Sell? - Defense World
Telsey Advisory Group Forecasts Macy’s’ Q2 Earnings (NYSE:M) - Defense World
D. E. Shaw & Co. Inc. Purchases 12,217 Shares of Arcos Dorados Holdings Inc. (NYSE:ARCO) - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Position Lowered by D. E. Shaw & Co. Inc. - Defense World
4DMT to Participate in Upcoming Investor Conferences | FDMT Stock News - GuruFocus
4DMT to Participate in Upcoming Investor Conferences - Eagle-Tribune
4D Molecular Therapeutics (NASDAQ:FDMT) Receives Sell (E+) Rating from Weiss Ratings - Defense World
Millennium Management LLC Acquires 1,337,497 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics’ SWOT analysis: gene therapy stock faces durability challenges amid pipeline progress - Investing.com
Deutsche Bank AG Sells 560,784 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Acquired by Northern Trust Corp - Defense World
BNP Paribas Financial Markets Makes New Investment in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Spotlight On 3 Penny Stocks With Market Caps Under $500M - Yahoo Finance
Jane Street Group LLC Increases Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by Price T Rowe Associates Inc. MD - Defense World
Dimensional Fund Advisors LP Cuts Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4DMT Boosts Talent Acquisition: 31,800 RSUs Granted as Biotech Firm Accelerates Growth - Stock Titan
FY2025 EPS Estimates for FDMT Decreased by Cantor Fitzgerald - Defense World
HC Wainwright Analysts Boost Earnings Estimates for FDMT - Defense World
Chardan Adjusts Price Target on 4D Molecular Therapeutics to $25 From $28, Maintains Buy Rating - marketscreener.com
Hsbc Holdings PLC Grows Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Barclays Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $38.00 - Defense World
Chardan Capital Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $25.00 - Defense World
The Goldman Sachs Group Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $44.00 - Defense World
Wells Fargo & Company MN Boosts Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (E+)” Rating at Weiss Ratings - Defense World
Contrasting Genfit (NASDAQ:GNFT) & 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
Barclays Adjusts Price Target for 4D Molecular (FDMT) | FDMT Sto - GuruFocus
RBC Cuts Price Target on 4D Molecular Therapeutics to $26 From $35, Keeps Outperform, Speculative Risk - marketscreener.com
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by Barclays PLC - The AM Reporter
Barclays Adjusts Price Target for 4D Molecular (FDMT) | FDMT Stock News - GuruFocus
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $26.71 Consensus Price Target from Brokerages - Defense World
4D Molecular Therapeutics Reports Increased Quarterly Loss - TipRanks
0.29%
자본화:
|
볼륨(24시간):